Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: KIM-1

Search for Biomarkers

Analyte:

KIM-1

Platform:

Status:

Experienced Running

Required Sample Volume:

50 µL/well

Sensitivity-LLOQ/ULOQ:

LLOQ: 2.00 pg/mL
ULOQ: 18,000 pg/mL

Biological or Clinical Significance:

The kidney injury molecule-1 (designated as Kim-1 in rodents, KIM-1 in humans) is expressed, at much lower levels, in lymphocytes and has also been referred to as T-cell immunoglobulin mucin (TIM)-1 and HAVCR-1, hepatitis A virus cellular receptor-1. The protein has also been reported to be expressed in the cochlea in response to cisplatin-induced injury [8]. The KIM/TIM family consists of eight members in mice, six in rats and three in humans.
KIM-1 is a type I cell membrane glycoprotein which contains, in its extracellular portion, a novel six-cysteine immunoglobulin-like domain, two N-glycosylation sites and a T/SP rich domain characteristic of mucin-like O-glycosylated proteins.

KIM-1 is a phosphatidylserine receptor that recognizes apoptotic cells directing them to lysosomes. It also serves as a receptor for oxidized lipoproteins and hence is adept at recognizing apoptotic cell ‘eat me’ signals. Given these properties KIM-1 is unique in being the first non-myeloid phosphatidylserine receptor that transforms epithelial cells into semi-professional phagocytes [13,14].

A number of characteristics of KIM-1 show that the protein is an ideal biomarker of kidney injury: the absence of KIM-1 expression in the normal kidney; its marked upregulation and insertion into the apical membrane of the proximal tubule; its persistence in the epithelial cell until the cell has completely recovered; the rapid and robust cleavage of the ectodomain and the ex vivo room temperature stability of the ectodomain.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies